What Is New in Neuromodulation?

AbstractNeuromodulation encompassing sacral and peripheral modalities is an established, effective, and safe higher-order treatment option approved in the USA for managing refractory overactive bladder, non-obstructive urinary retention, and fecal incontinence. This review highlights the most recent literature, indications, treatment durability, and the latest innovations in this field. Regarding sacral neuromodulation (SNM), recent work suggests improved parameters for optimal lead placement, increased data to support the lasting effects of treatment, and novel applications of this technology to other pelvic disorders. In addition, there are emerging technologies with smaller MRI compatible devices. Newer data on percutaneous tibial nerve stimulation (PTNS) suggests it may be more beneficial for certain patients. With new technology, implantable tibial nerve stimulators are ushering in a new frontier of nerve stimulation in the comfort of the patient ’s home.
Source: Current Urology Reports - Category: Urology & Nephrology Source Type: research

Related Links:

Abstract PURPOSE: Recurrent bacterial cystitis is a common infection in women and there are concerns about its antibiotic therapy. Platelet rich plasma has antimicrobial and tissue repairing effects. We investigated the effect of platelet rich plasma as an intravesical therapy to prevent recurrence of bacterial cystitis. Materials and Methods: Thirty women with a history of recurrent bacterial cystitis were randomly assigned into two groups: 1) platelet rich plasma and 2) control groups. The first group received 10 mL of platelet rich plasma with intravesical instillation plus 40 mL of normal saline. The cont...
Source: Urology Journal - Category: Urology & Nephrology Authors: Tags: Urol J Source Type: research
ConclusionsClinical impression may not adequately assess frailty. Miscategorization of frailty by FPMRS providers was higher than in other fields.
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
Funding Opportunity RFA-DK-19-015 from the NIH Guide for Grants and Contracts. The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. This FOA ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Funding Opportunity RFA-DK-19-016 from the NIH Guide for Grants and Contracts. The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. The purpo...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. This FOA is to invite applications for Clinical Research Centers to build on foundational...
Source: NIDDK Funding Opportunities - Category: Endocrinology Source Type: funding
The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for ...
Source: NIDDK Funding Opportunities - Category: Endocrinology Source Type: funding
This article really demonstrated and did a very nice job in separating out the different types of anticholinergic medications and, specifically, the anticholinergic medications to treat overactive bladder, which is the primary pharmacological intervention that we have," Noblett said. The researchers analyzed the data by type of burden and level of burden (low, medium, high) and found that the risk of dementia, even in the low burden, went up by 19% and in the high burden was up by 60%.  "And those were just for patients with the overactive bladder anticholinergic,&q...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Conclusion Mirabegron is safe, effective and tolerable in the long-term treatment of females with OAB symptoms after surgery for s tress urinary incontinence.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
ConclusionsMost patients with OAB and normal PVR complain of OVS which may increase the burden on their QoL and sexual function. Some OVS correlate with various segments of the UDI-6 and IIQ-7 questionnaires, suggesting that storage and OVS may share common pathophysiological mechanisms.
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
Publication date: Available online 13 August 2019Source: European UrologyAuthor(s): Christian Gratzke, Christopher Chapple, Elizabeth R. Mueller, Dudley Robinson, Catherine Rolland, David Staskin, Matthias Stoelzel, Rob van Maanen, Emad SiddiquiAbstractContextOral pharmacotherapy consisting of antimuscarinics, β3-adrenoreceptor agonists, or combinations of these agents forms the mainstay of overactive bladder (OAB) management.ObjectiveTo evaluate the efficacy and safety of combination therapy in patients with OAB.Evidence acquisitionA literature search was conducted in June 2018 using Embase, MEDLINE, and Cochrane dat...
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Brain | Incontinence | Neurology | Overactive Bladder | Overactive Bladder Syndrome | Urology & Nephrology